A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2015; you can also visit the original URL.
The file type is application/pdf
.
Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics
2013
International Journal of Nanomedicine
Pyridostigmine bromide (3-[[(dimethylamino)-carbonyl]oxy]-1-methylpyridinium bromide), a reversible inhibitor of cholinesterase, is given orally in tablet form, and a treatment schedule of multiple daily doses is recommended for adult patients. Nanotechnology was used in this study to develop an alternative sustained-release delivery system for pyridostigmine, a synthetic drug with high solubility and poor oral bioavailability, hence a Class III drug according to the Biopharmaceutics
doi:10.2147/ijn.s40860
pmid:23459707
pmcid:PMC3582480
fatcat:tnq3q3pwobeinfrnybvn7ybqz4